

# Effect of salicylate on the large GABAergic neurons in the inferior colliculus of rats

Qiao-Zhi Zou · Xiu-Li Shang

Received: 14 March 2012 / Accepted: 15 May 2012 / Published online: 30 May 2012  
© Belgian Neurological Society 2012

**Abstract** Salicylate, the anti-inflammatory component of aspirin, induces transient tinnitus and hearing loss in clinical and animal experiments. However, the affected sites and mechanisms of generation remain unclear. Recently, down-regulation of inhibitory transmission mediated by  $\gamma$ -aminobutyric acid type A receptors was suggested to be crucial in generating tinnitus. However, the cell-specific pathways involved in this process were far from being understood. Here, we describe changes of inhibitory neurotransmitter, receptor, and glutamatergic axosomatic terminals in certain large GABAergic neurons (LGNs) in the inferior colliculus of rats treated with high doses of salicylate. Based on these results, we suggest that salicylate may affect inhibitory projection pathways from the inferior colliculus to the auditory cortex and lead to neural hyperactivity, perhaps by affecting the function of the LGNs.

**Keywords** Salicylate · GABAergic neurons · VGLUT2 · Inhibitory projection

## Introduction

Tinnitus is the perception of phantom sounds in the absence of acoustic stimuli. High doses of salicylate reliably induce transient tinnitus in humans and animals [1, 2].

**Electronic supplementary material** The online version of this article (doi:10.1007/s13760-012-0090-5) contains supplementary material, which is available to authorized users.

Q.-Z. Zou · X.-L. Shang (✉)  
Department of Neurology, Affiliated First Hospital,  
China Medical University, No. 155 Nanjingbei Road,  
Heping District, Shenyang 110001, People's Republic of China  
e-mail: shang\_zhao@sina.cn

Current thinking on the mechanism of tinnitus is that salicylate-induced neural changes upset the balance between excitatory and inhibitory brain processes, resulting in neural hyperactivity. Recently, Sun et al. [3] indicated that high doses of salicylate increased the gain of the central auditory system, presumably by down-regulating inhibition mediated by  $\gamma$ -aminobutyric acid type A (GABA<sub>A</sub>) receptors. However, the cell-specific pathways involved in this process are still far from being understood.

The ascending auditory pathway is from the cochlea through tonotopically organized nuclei in the brainstem, the inferior colliculus (IC) of the midbrain, and the medial geniculate body (MGB) of the thalamus, ascending eventually to the neocortex. Several studies suggest that the IC is a potential candidate as the locus of tinnitus generation [4, 5]. Winer et al. [6] affirmed the existence of inhibitory projection from GABAergic neurons in the IC to the MGB. Recently, Ito et al. [7] reported that the large GABAergic neurons (LGNs), which are densely covered with vesicular glutamate transporter 2 (VGLUT2)<sup>+</sup> glutamatergic axosomatic endings, may be the primary source of GABAergic tectothalamic inputs to the MGB. In our preliminary immunohistochemistry studies, we found that intense GABA<sub>A</sub> receptor  $\alpha$ 1 subunit (GABA<sub>A</sub> $\alpha$ 1) immunoreactions appeared in a certain type of cells in the IC of rats. The size and distributed sites were both similar to that of the LGNs. Thus, in the present study, we first used real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis to determine if any changes in the GABA<sub>A</sub> subunit and glutamic acid decarboxylase (GAD) mRNA expression could be found after treatment with high doses of salicylate. Then, laser confocal microscopy was used to determine if similar changes could be found in the LGNs. We hypothesized that specific changes could occur in the LGNs after administration of salicylate, which may further

affect the inhibitory projection from the IC to the MGB and contribute to hyperactivity in the IC in rats.

## Methods

### Animals and operative procedures

Twenty-six adult SPF Sprague–Dawley rats, 14–15 weeks of age and weighing 250–350 g (Institute of Animal, China Medical University, Shen Yang, China; certified by the Department of Science and Technology of Liaoning Province, certificate NO.SCXX [Liao] 2008–0005), were randomly divided into experimental and control groups. All animals were fed under the same conditions at the Institute of Animal. Sodium salicylate (Sigma-Aldrich, St. Louis, MO, USA) at an intraperitoneal dose of 350 mg/kg (20 mg/mL solution) and an equal volume of 0.9 % saline were administered to rats in the experimental group and the control group, respectively, for 5 consecutive days. The concentration of salicylate and the injection time course had been confirmed to reliably induce tinnitus in rats [2]. On the sixth day, all rats were deeply anesthetized with 4 % chloral hydrate (3.5 mL/kg). The ICs from 20 rats (10 controls, 10 salicylate-treated) were removed within 5 min to avoid destruction of the protein and mRNA. The samples were immediately stored at  $-80^{\circ}\text{C}$  until real-time RT-PCR was performed. The remaining six rats (3 controls, 3 salicylate-treated) were transcardially perfused with fixative (4 % paraformaldehyde, buffered with 0.1 M phosphate buffer [PB] to pH 7.4). Brains were removed and post-fixed in the same fixative until sectioning for immunohistochemistry examination. The experimental procedures were performed in accordance with the principles of animal care outlined by the Chinese Academy of Sciences. Efforts were made to minimize animal use and suffering.

Total RNA isolation, reverse transcription, and real-time RT-PCR

Total RNA of the ICs from ten rats in each group was isolated using the Qiagen RNeasy kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. cDNA was prepared from total RNA using oligo primers and superscript reverse transcriptase according to the accompanying protocol (Clontech, Palo Alto, CA, USA). The specific primers were for rat  $\beta$ -actin and GABA $_{\text{A}}$  $\alpha$ 1,  $\beta$ 2 and  $\gamma$ 2 subunits, and GAD65 and GAD67 (Table 1). Quantitative real-time PCR was performed in the Quantitect SYBR Green PCR kit (Rotorgene 2000, Corbett Research, Sydney, Australia). The amplification of  $\beta$ -actin RNA was used as an internal control. The data were analyzed by the comparative Ct method. After each real-time RT-PCR, a melting profile and agarose gel electrophoresis of each sample were performed to rule out nonspecific PCR products and primer dimers.

### Immunohistochemistry procedure

After post-fixation for 4 h, the samples were cryoprotected with 30 % sucrose in phosphate-buffered saline (PBS) overnight at  $4^{\circ}\text{C}$ . When the samples all sank to the bottom of the container, serial coronal sections were cut at a thickness of 20  $\mu\text{m}$  using a freezing microtome; every fifth section was used for histology. Sections were incubated with 12 % normal donkey serum for 1 h at room temperature in PBS, followed by incubation with the primary antibodies overnight in the same buffer. The primary antibodies used were monoclonal mouse anti-VGLUT2 (1:200; 8G9.2, Abcam, MA, USA), polyclonal goat anti-GABA $_{\text{A}}$  $\alpha$ 1 (1:200, Santa Cruz Biotechnology, CA, USA), polyclonal rabbit anti-GAD67 (1:200; ab97739, Abcam). All antibodies were diluted in incubation buffer (1 % bovine serum albumin, PBS, and 0.3 % Triton X-100). The specificities of the VGLUT2 and GAD67

**Table 1** Primers used for real-time RT-PCR analysis

Gene	Sequence (forward and reverse primer)	NCBI Gene ID
GABA $_{\text{A}}$ $\alpha$ 1	5'-AAG GAC CCA TGA CAG TGC TC-3' 5'-GGC TCC CTT GTC CAC TCA TA-3'	29,705
GABAA $\beta$ 2	5'-GTGCCTGACACCTACTTCCTG-3' 5'-TAGCCATAGCTTTTCGATCTCC-3'	25,451
GABAA $\gamma$ 2	5'-GACGATGACCACTCTCAGCA-3' 5'-CAGTCCTTGCCATCCAAAC-3'	29,709
GAD65	5'-GTACGCCATGCTCATTGCC-3' 5'-AGAGAGGATCAAAAGCCCCG-3'	24,379
GAD67	5'-GCTGGAAGGCATGGAAGGTTTTA-3' 5'-ACGGGTGCAATTTTCATATGTGAACATA-3'	24,380
$\beta$ -Actin	5'-TGT GAT GGT GGG AAT GGG TCA G-3' 5'-TTT GAT GTC ACG CAC GAT TTC C-3'	81,822

antisera were demonstrated by Western blotting (according to the manufacturer's datasheet). The specificity of the GABA<sub>A</sub>α1 antiserum was verified by Western blotting as described previously [8]. The next day, sections were washed and incubated with secondary antibodies that were raised from donkey and conjugated with fluorescein isothiocyanate (FITC), texas red (TR) and dylight 405 (1:200, Jackson, PA, USA). Controls were routinely carried out by replacing the primary antisera with normal sera. Sections were mounted on coated slides, air dried, rehydrated, and cover-slipped with 1,4-diazabicyclo [2.2.2]octane (DABCO).

### Image acquisition

All the triple-labeled images were captured on an FV1000S-SIM/IX81 laser confocal scanning microscope, LCSM (Olympus, Tokyo, Japan) in *X Y Z* plane using a 100× oil immersion objective. To minimize the error produced in this process, we invited two experienced pathologists to assist and adopted a double-blind method. For each animal, we analyzed 4–6 alternate sections. Only the cells labeled with GAD67 and covered with VGLUT2<sup>+</sup> axosomatic terminals were the targeted LGNs. All the LGNs were selected from the central nucleus. No more than three LGNs per section that were intact morphologically were carefully traced and scanned using confocal microscopy. Finally, we obtained 20 satisfactory neurons in either group. To quantify the GABA<sub>A</sub>α1 and GAD67 protein levels in the LGNs, the Z-stacks (18–22 optical slices) were obtained at a thickness of 0.7 μm optical sections. Within each selected field of view, the 5th and 15th optical slices were analyzed, respectively. The cell body and the most proximal parts of the processes were outlined for digitalization of area and of fluorescence intensity for immunoreactivities with the laser scanning microscope LSM 510 version 2.5 software. For quantifying the VGLUT2 in the axosomatic terminals apposing GABAergic neurons, we chose five neurons whose long axes were parallel to the section plane for statistical analysis in either group among the 20 neurons. The Z-stacks (38–42 optical slices) were obtained at a thickness of 0.2 μm optical sections. The Z-stacks were then converted into a three-dimensional (3D) projection using Image J (1.43u). The contrast adjustment of the 3D projection images was consistent for all selected neurons to clearly show the profile of the neurons. For the Z-stack of every GABAergic neuron we chose, the 8th, 16th, 24th, and 32nd optical slices were analyzed. The surfaces of somata and dendrites were outlined for area and fluorescence intensity analysis. The parameters for digitizing photomicrographs were determined in a pilot study with optimal contrast between labeling and background and were then kept constant across conditions and animals.

### Statistical analysis

The graphs and statistical analyses were performed using SPSS v13.0. All results were expressed as mean ± SE (*n*), where *n* refers to the number of samples. Data were normal distribution in both groups, we performed the two-tailed Student *t* test. The Levene test was used for equality of variances. The significance level was set at *P* < 0.05.


## Results

### mRNA expression


The mRNA levels of the GABA<sub>A</sub>α1, β2, and γ2 subunits and GAD65 and GAD67 in normal and salicylate-treated rats were analyzed by real-time RT-PCR. Data from the salicylate-treated group are expressed as fold changes compared with controls. The data shown in Fig. 1 demonstrate that mRNA expression of GABA<sub>A</sub>α1 and GAD67 in salicylate-treated animals were significantly lower (0.43- and 0.40-fold, respectively) than levels in the control animals (*P* < 0.05, *P* < 0.01); no such differences in GABA<sub>A</sub>β2 and γ2 and GAD65 were found between the two groups (0.89-, 1.56-, and 0.84-fold, respectively; *P* > 0.05). The results indicate that high doses of salicylate significantly down-regulated the mRNA expression of GABA<sub>A</sub>α1 and GAD67, but had no such effect on the mRNA expression of GABA<sub>A</sub>β2 and γ2 or GAD65.

### Protein expression of GABA<sub>A</sub>α1 and GAD67 in the LGNs

The distribution and expression of GABA<sub>A</sub>α1 and GAD67 protein in the LGNs of normal and salicylate-treated rats



**Fig. 1** Quantitative gene expression profile of the GABA<sub>A</sub>α1, β2, and γ2 subunits and GAD65 and GAD67 from IC of the salicylate-treated group and the control group by real-time RT-PCR. Data from the salicylate-treated group are expressed as fold changes compared with controls (\**P* < 0.05, \*\**P* < 0.01)




**Fig. 2** Laser confocal image of the IC section, stained for VGLUT2 (red), GAD67 (green) and GABA<sub>A</sub>α<sub>1</sub> (blue). **a–d** Examples from control animals. **e–h** Examples from salicylate-treated animals. **c, g** The results of merging from red and green channels. Arrows point

to the LGNs, which are determined by labeling with GAD67 in the cell bodies and dendrites and covered with VGLUT2<sup>+</sup> axosomatic terminals ( $\times 1000$ , scale bars 10  $\mu\text{m}$ ) (color figure online)

were examined with laser confocal microscopy from sections triple-stained with GAD67, VGLUT2 and GABA<sub>A</sub>α<sub>1</sub> markers. As shown in Fig. 2, in the LGNs, which were determined by GAD67 staining in the cell body and dendrites and covered with VGLUT2<sup>+</sup> axosomatic terminals (Fig. 2c, g), GABA<sub>A</sub>α<sub>1</sub> and GAD67 proteins were both present in the neuronal cytoplasm and cytomembrane as well as protrusions. Because the nuclei are unlabeled, the center of the

neurons seemed to be relatively dark. Fluorescence intensity for immunoreactivities was used to determine the levels of protein expression. Data are shown in Fig. 3. Specifically, the mean fluorescence intensity (MFI) of GAD67 and GABA<sub>A</sub>α<sub>1</sub> in the LGNs of control animals was  $96.2 \pm 16.7$  and  $72.2 \pm 9.9$ , respectively, whereas values were  $78.3 \pm 13.3$  and  $47.5 \pm 8.4$ , respectively, in the salicylate-treated animals. The statistical results indicate that in the LGNs, of




**Fig. 2** continued

all 20 neurons in either group, the MFI value of GAD67 and GABA<sub>A</sub>α1 were both significantly decreased after salicylate treatment ( $P < 0.05$ ).


#### VGLUT2<sup>+</sup> glutamatergic axosomatic terminals

As shown in Fig. 2a, e, VGLUT2 staining created a punctate staining pattern, and the VGLUT2<sup>+</sup> axosomatic terminals directly apposed the somata and dendrites of LGNs we traced. To determine the profile of the LGNs, ten

LGNs were scanned, encompassing the whole cell body and dendrite, and converted to 3D projections as shown in Fig. 4a. The VGLUT2<sup>+</sup> axosomatic terminals were unevenly distributed on the cytomembrane surface of the LGNs. According to the profiles offered by 3D projection, we determined the area and fluorescence intensity of VGLUT2 in each selected neuron for analysis (Fig. 4b). Data are shown in Fig. 3. The MFI of VGLUT2 was  $114.4 \pm 19.0$  in control animals and  $102.4 \pm 22.8$  in salicylate-treated animals, not a significant difference,



**Fig. 3** Semi-quantitative analysis of MFI in either group. The MFIs of GAD67 and GABA $\alpha$ 1 in the LGNs of control animals are both significantly higher than those in the salicylate-treated animals. \* $P < 0.05$ ,  $n = 20$ ; but no significant changes occurred in the MFI of VGLUT2 between the two groups.  $P > 0.05$ ,  $n = 5$



**Fig. 4** 3D projection immunofluorescence images of the LGN. **a** Example of a selected LGN image from 42 0.2- $\mu$ m thick Z-stacks. The LGN (green) is densely covered with unevenly distributed VGLUT2<sup>+</sup> glutamatergic axosomatic endings (red). The profile of the neurons is clearly demonstrated (for animated projections, see Supplemental Movie 1) (scale bars 5  $\mu$ m). **b** Image of the 24th optical slice from this Z-stacks. The surface of somata and dendrites is clearly shown and was outlined for area and fluorescence intensity analysis (scale bars 5  $\mu$ m) (color figure online)

indicating that no significant changes occurred in VGLUT2 protein expression in the axosomatic terminals after salicylate treatment ( $P > 0.05$ ).

## Discussion

### Activity dependence of GABA $\alpha$ 1 and GAD67 transcription

As we showed, high doses of salicylate significantly decreased GABA $\alpha$ 1 and GAD67 mRNA expression, but had no effect on the  $\beta$ 2 and  $\gamma$ 2 subunit protein expression during this process. We know that the main GABA $\alpha$  subunits transcribed in the IC of rats are the  $\alpha$ 1,  $\beta$ 2, and  $\gamma$ 2 subunits, but the  $\alpha$ 1 subunit is much more transcribed than the other two [9]. Several lines of evidence suggest that expression of the  $\alpha$ 1 subunit is activity dependent [10].

Various mechanisms are likely to be involved in a complex system of regulatory control for the transcription of GABA $\alpha$ 1, for example, Hu et al. [11] supposed that activation of protein kinase C and protein kinase A could regulate the cell surface expression of  $\alpha$ 1 subunit. GABA is synthesized by two GADs, GAD67 and GAD65 (encoded by the *Gad1* and *Gad2* genes, respectively), and they show a striking difference in their gene regulation [12]. The major step in the physiologic regulation of GAD67 activity is *Gad1* transcription, which is dynamically regulated during development and by neural activity [13]. In this case, the  $\alpha$ 1 subunit and GAD67 mRNA expression in the IC of salicylate-treated rats may have been altered by these manipulations.

Levels of GABA $\alpha$ 1 and GAD67 may affect the function of LGNs

GABA synthesis is the rate-limiting step in GABA metabolism, which readily influences the cellular and vesicular GABA content [14]. GAD67 catalyzes the synthesis of GABA from glutamate and is responsible for >90 % of basal GABA synthesis. Knockdown of GAD67 in a single GABAergic interneuron results in a profound cell autonomous defect in cortical organotypic cultures [15]. Down-regulation of the GAD67 level in the LGNs may result in decrease of the intracellular GABA pool for release. Neurons communicate through the exocytotic release of transmitters from presynaptic axon terminals and the ensuing activation of postsynaptic receptors. Exocytotic transmitter release is modulated by a variety of mechanisms. The GABA released by the LGNs may be modulated by the GABA $\alpha$  receptors in the LGN, because several studies attested that GABA $\alpha$  receptors could control GABA release via presynaptic modulations [16]. But the exact effect is uncertain in the LGNs, because the actions are various at different sites of brain [17, 18].

GABA $\alpha$  receptors are heteropentameric membrane proteins constituting the GABA-gated chloride channels. Binding of GABA to its receptor opens the ionophore and increases chloride conductance, which leads to neuronal inhibition [19]. We have known that the  $\alpha$ 1 subunit participates in the formation of the functional benzodiazepine-binding site and neurosteroid-binding sites in GABA $\alpha$  receptors [20, 21]. In electrophysiological studies, it produces fast current decay and confers sensitivity to imidazopyridine, zolpidem [18]. So significantly decreased levels of the  $\alpha$ 1 subunit protein may seriously affect the function of the GABA $\alpha$  receptors in the LGNs. The efficacy of inhibitory neurotransmission strongly depends on the kinetics of the postsynaptic receptor channels. Previous study with cultured rat hippocampal neurons showed that salicylate reduced the GABAergic transmission mainly by

suppressing GABA<sub>A</sub> receptor-mediated responses [22]. And several studies demonstrated that the kinetics of IPSCs varied with the  $\alpha 1$  subunit [18]. So the decrease of GABA<sub>A</sub> $\alpha 1$  in the present study was likely to cause decrease of inhibition possibly through affecting the function of the GABA<sub>A</sub> receptor. The LGNs were proposed to be the primary source of GABAergic tectothalamic inputs to the MGB and could produce monosynaptic inhibitory postsynaptic potentials (IPSPs) in thalamocortical relay neurons there [7, 23]. In this manner, the LGNs provide strong inhibitory GABAergic inputs to the MGB and further delivery to the auditory cortex. However, GABAergic and glutamatergic neurons both constitute the MGB projection [6, 23], and their axons both pass through the brachium of the IC (BIC). When the BIC is stimulated electrically, IPSPs appear in the MGB before the excitatory postsynaptic potentials (EPSPs) [23]. Down-regulation of the GAD67 and GABA<sub>A</sub> $\alpha 1$  protein expression in the LGNs will lead to inadequate GABA and GABA<sub>A</sub> receptor synthesis, which may affected the inhibitory transmission mediated by the LGNs and destroy the balance between excitation and inhibition, probably by slowing down the conducted velocity of IPSPs from the IC to the MGB.

The VGLUT2<sup>+</sup> axosomatic terminals were relatively constant to the salicylate treatment

The VGLUT2 proteins are members of the solute carrier family Slc17a6-8, act as vesicular glutamate transporters, and mediate the packaging of the excitatory neurotransmitter glutamate into synaptic vesicles [24]. The presence of vesicular glutamate transporters has been a useful immunohistochemical marker for glutamatergic terminals. In the present study, we did not count the number of the VGLUT2<sup>+</sup> axosomatic terminals apposing the neurons as previous studies reported [25], because VGLUT immunoreactivity is correlated with quantal release of glutamate [26], and the fluorescence intensity of VGLUT2 immunoreactivity should be an indication of the amount of glutamatergic transmission inputs to the LGNs. In contrast, the number of VGLUT2<sup>+</sup> terminals is not equal to the quantity of the neurotransmitter in the terminals. Several studies demonstrated that the LGNs received VGLUT2<sup>+</sup> glutamatergic input through axosomatic terminals in the IC of rats, but little was known about the origin and function of these terminals. One report suggested that it helped the LGNs fire more quickly and made IPSPs arrive in the auditory thalamus before the EPSPs [7]. In the present study, we found no difference in the VGLUT2 protein expression in the axosomatic terminals after salicylate treatment, which means the amount of glutamatergic transmission was relatively constant with salicylate treatment. Perhaps the axosomatic synapses

offer little to the neural hyperactivity caused by salicylate treatment.

## Conclusion

In the present study, we found a significant decrease of GABA<sub>A</sub> $\alpha 1$  and GAD67 in the IC and in the LGNs of rats after salicylate treatment, which may affect the GABAergic transmission from the IC to the MGB mediated by the LGNs. However, although the salicylate model of tinnitus used in the present study is an established model, it uses doses of salicylate greater than physiologic doses. This high dose of salicylate will maybe induce unwanted consequences such as hypernatremia or hyperacidosis. Although no evidence indicated that the side effects of salicylate had any effects on the proteins examined in the present study, efforts will be made in the future to reduce these possible influences using high doses of salicylate.

**Acknowledgments** This work was supported by Grant 30700938 from the National Natural Science Foundation of China; Grant L2010564 from the Foundation of Liaoning Province education office. We wish to thank GAO Jian and XU Hong-Tao for assistance with image analysis.

**Conflict of interest** None.

## References

- Brien JA (1993) Ototoxicity associated with salicylates. A brief review. *Drug Saf* 9:143–148
- Jastreboff PJ, Brennan JF, Sasaki CT (1988) An animal model for tinnitus. *Laryngoscope* 98:280–286
- Sun W, Lu J, Stolzberg D et al (2009) Salicylate increases the gain of the central auditory system. *Neuroscience* 159:325–334
- Basta D, Ernst A (2004) Effects of salicylate on spontaneous activity in inferior colliculus brain slices. *Neurosci Res* 50:237–243
- Bauer CA, Brozoski TJ, Holder TM, Caspary DM (2000) Effects of chronic salicylate on GABAergic activity in rat inferior colliculus. *Hear Res* 147:175–182
- Winer JA, Saint Marie RL, Larue DT, Oliver DL (1996) GABAergic feedforward projections from the inferior colliculus to the medial geniculate body. *Proc Natl Acad Sci USA* 93:8005–8010
- Ito T, Bishop DC, Oliver DL (2009) Two classes of GABAergic neurons in the inferior colliculus. *J Neurosci* 29:13860–13869
- Milligan CJ, Buckley NJ, Garret M, Deuchars J, Deuchars SA (2004) Evidence for inhibition mediated by coassembly of GABA<sub>A</sub> and GABAC receptor subunits in native central neurons. *J Neurosci* 24:7241–7250
- Wisden W, Laurie DJ, Monyer H, Seeburg PH (1992) The distribution of 13 GABA<sub>A</sub> receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. *J Neurosci* 12:1040–1062
- Harris BT, Charlton ME, Costa E, Grayson DR (1994) Quantitative changes in alpha 1 and alpha 5 gamma-aminobutyric acid

- type A receptor subunit mRNAs and proteins after a single treatment of cerebellar granule neurons with *N*-methyl-D-aspartate. *Mol Pharmacol* 45:637–648
11. Hu Y, Lund IV, Gravielle MC, Farb DH, Brooks-Kayal AR, Russek SJ (2008) Surface expression of GABA<sub>A</sub> receptors is transcriptionally controlled by the interplay of cAMP—response element-binding protein and its binding partner inducible cAMP early repressor. *J Biol Chem* 283:9328–9340
  12. Pinal CS, Tobin AJ (1998) Uniqueness and redundancy in GABA production. *Perspect Dev Neurobiol* 5:109–118
  13. Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM (2006) A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. *J Neurosci* 26:1604–1615
  14. Engel D, Pahner I, Schulze K et al (2001) Plasticity of rat central inhibitory synapses through GABA metabolism. *J Physiol* 535:473–482
  15. Ji F, Obata K (1999) Development of the GABA system in organotypic culture of hippocampal and cerebellar slices from a 67-kDa isoform of glutamic acid decarboxylase (GAD67)-deficient mice. *Neurosci Res* 33:233–237
  16. Farrant M, Nusser Z (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA<sub>A</sub> receptors. *Nat Rev Neurosci* 6:215–229
  17. Okada M, Onodera K, Van Renterghem C, Sieghart W, Takahashi T (2000) Functional correlation of GABA<sub>A</sub> receptor  $\alpha$  subunits expression with the properties of IPSCs in the developing thalamus. *J Neurosci* 20:2202–2208
  18. Vicini S, Ferguson C, Prybylowski K, Kralic J, Morrow AL, Homanics GE (2001) GABA(A) receptor alpha1 subunit deletion prevents developmental changes of inhibitory synaptic currents in cerebellar neurons. *Neuroscience* 21:3009–3016
  19. Hamill OP, Bormann J, Sakmann B (1983) Activation of multiple-conductance state chloride channels in spinal neurones by glycine and GABA. *Nature* 305:805–808
  20. Boileau AJ, Czajkowski C (1999) Identification of transduction elements for benzodiazepine modulation of the GABA(A) receptor: three residues are required for allosteric coupling. *J Neurosci* 19:10213–10220
  21. Hosie AM, Wilkins ME, da Silva HM, Smart TG (2006) Endogenous neurosteroids regulate GABA<sub>A</sub> receptors through two discrete transmembrane sites. *Nature* 444:486–489
  22. Gong N, Zhang M, Zhang XB, Chen L, Sun GC, Xu TL (2008) The aspirin metabolite salicylate enhances neuronal excitation in rat hippocampal CA1 area through reducing GABAergic inhibition. *Neuropharmacology* 54:454–463
  23. Peruzzi D, Bartlett E, Smith PH, Oliver DL (1997) A monosynaptic GABAergic input from the inferior colliculus to the medial geniculate body in rat. *J Neurosci* 17:3766–3777
  24. Reimer RJ, Edwards RH (2004) Organic anion transport is the primary function of the SLC17/type I phosphate transporter family. *Pflugers Arch* 447:629–635
  25. Khan M, De Sevilla L, Mahesh VB, Brann DW (2010) Enhanced glutamatergic and decreased GABAergic synaptic appositions to GnRH neurons on proestrus in the rat: modulatory effect of aging. *PLoS ONE* 5:e10172
  26. Moechars D, Weston MC, Leo S et al (2006) Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain. *J Neurosci* 26:12055–12066